DrugPatentWatch Database Preview

Astrazeneca Pharms Company Profile

ASTRAZENECA PHARMS has nineteen approved drugs.

There are sixty-six US patents protecting ASTRAZENECA PHARMS drugs.

There are one thousand two hundred and twenty-five patent family members on ASTRAZENECA PHARMS drugs in sixty-seven countries and one hundred and thirty-three supplementary protection certificates in seventeen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	BRILINTA	ticagrelor	TABLET;ORAL	022433-001	Jul 20, 2011	AB	RX	Yes	Yes	7,250,419	Start Trial	Y	Y		Start Trial
Astrazeneca Pharms	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995		DISCN	Yes	No	6,191,148*PED	Start Trial				Start Trial
Astrazeneca Pharms	LYNPARZA	olaparib	TABLET;ORAL	208558-002	Aug 17, 2017		RX	Yes	Yes	8,859,562	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Pharms	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995	4,508,905*PED	Start Trial
Astrazeneca Pharms	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995	5,599,794*PED	Start Trial
Astrazeneca Pharms	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022101-001	Feb 27, 2008	6,369,085*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release for Oral Suspension	2.5 mg and 5 mg	➤ Subscribe	2018-09-24
➤ Subscribe	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL	➤ Subscribe	2005-09-15
➤ Subscribe	Delayed-release Capsules	20 mg	➤ Subscribe	2007-03-19
➤ Subscribe	Tablets	90 mg	➤ Subscribe	2015-07-20
➤ Subscribe	Tablets	500 mcg	➤ Subscribe	2015-03-02
➤ Subscribe	Tablets	25 mg	➤ Subscribe	2005-08-12
➤ Subscribe	Tablets	100 mg, 200 mg and 300 mg	➤ Subscribe	2006-02-21
➤ Subscribe	Delayed-release	20 mg and 40 mg	➤ Subscribe	2005-08-05
➤ Subscribe	For Injection	20 mg/vial and 40 mg/vial	➤ Subscribe	2009-11-23
➤ Subscribe	Inhalation Suspension	1 mg/2 mL	➤ Subscribe	2010-05-28
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2012-03-30
➤ Subscribe	Tablets	60 mg	➤ Subscribe	2015-09-30
➤ Subscribe	Tablets	12.5 mg and 25 mg	➤ Subscribe	2018-09-17
➤ Subscribe	Tablets	50 mg, 150 mg and 400 mg	➤ Subscribe	2007-02-12

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	1890030-8	Sweden	Start Trial	PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
2563920	CA 2019 00001	Denmark	Start Trial	PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710
2435025	LUC00124	Luxembourg	Start Trial	PRODUCT NAME: BEVESPI AEROSPHERE; AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.